Combination of “low-dose” ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy

Figure 1 Outcome of 34 HCV infected non-responders to IFN monotherapy, including response to combined therapy with IFN and “low-dose” ribavirin for 6 months, response to followed IFN monotherapy for 6 months for complete responders to combined therapy and outcome during follow up after 12 months treatment.

Figure 2 Outcome of 13 HCV-infected relapsers to IFN monotherapy, including response to combined therapy with IFN and “low-dose” ribivirin for 6 months, response to followed IFN monotherapy for 6 months for complete responders to combined therapy and outcome during follow-up after end of 12 months treatment.

Figure 3 Decrease of hemoglobin of 40 patients (34 non-responders and 13 relapsers to IFN monotherapy) who continued on combination therapy with IFN and “low-dose” ribavirin.